| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Editas Medicine Inc (NASDAQ: EDIT)
EDIT Technical Analysis
5
| As on 9th Jun 2023 EDIT STOCK Price closed @ 9.67 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 15.70 & Strong Sell for SHORT-TERM with Stoploss of 20.51 we also expect STOCK to react on Following IMPORTANT LEVELS. |
EDITSTOCK Price
| Open | 9.96 | Change | Price | % |
| High | 10.13 | 1 Day | 0.07 | 0.73 |
| Low | 9.38 | 1 Week | 0.49 | 5.34 |
| Close | 9.67 | 1 Month | 1.65 | 20.57 |
| Volume | 1620600 | 1 Year | -20.15 | -67.57 |
| 52 Week High 30.20 | 52 Week Low 6.36 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| EDIT Daily Charts |
EDIT Intraday Charts |
Whats New @ Bazaartrend |
EDIT Free Analysis |
|
|
EDIT Important Levels Intraday
| RESISTANCE | 11.12 |
| RESISTANCE | 10.65 |
| RESISTANCE | 10.37 |
| RESISTANCE | 10.08 |
| SUPPORT | 9.26 |
| SUPPORT | 8.97 |
| SUPPORT | 8.69 |
| SUPPORT | 8.22 |
EDIT Forecast May 2024
| 4th UP Forecast | 30.98 |
| 3rd UP Forecast | 24.15 |
| 2nd UP Forecast | 19.92 |
| 1st UP Forecast | 15.7 |
| 1st DOWN Forecast | 3.64 |
| 2nd DOWN Forecast | -0.58 |
| 3rd DOWN Forecast | -4.81 |
| 4th DOWN Forecast | -11.64 |
EDIT Weekly Forecast
| 4th UP Forecast | 17.96 |
| 3rd UP Forecast | 15.30 |
| 2nd UP Forecast | 13.66 |
| 1st UP Forecast | 12.01 |
| 1st DOWN Forecast | 7.33 |
| 2nd DOWN Forecast | 5.68 |
| 3rd DOWN Forecast | 4.04 |
| 4th DOWN Forecast | 1.38 |
EDIT Forecast2024
| 4th UP Forecast | 56.13 |
| 3rd UP Forecast | 41.23 |
| 2nd UP Forecast | 32.02 |
| 1st UP Forecast | 22.81 |
| 1st DOWN Forecast | -3.47 |
| 2nd DOWN Forecast | -12.68 |
| 3rd DOWN Forecast | -21.89 |
| 4th DOWN Forecast | -36.79 |
Editas Medicine Inc ( NASDAQ USA Symbol : EDIT )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
EDIT Business Profile
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary genome editing platform based on CRISPR technology to target genetically addressable diseases and therapeutic areas. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis type 10, a genetic form of vision loss that leads to blindness in childhood. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa 4, a progressive form of retinal degeneration; and EDIT-301 to treat sickle cell disease and beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumors; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer, as well as has a early discovery program to develop a therapy to treat a neurological disease. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and research collaboration with Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease, as well as research collaboration with AskBio and collaboration with m BlueRock Therapeutics LP. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts. Address: 11 Hurley Street, Cambridge, MA, United States, 02141
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service